With little effective treatment options for the disease other than surgical resection, systemic treatment of RCC now includes a wealth of options, including inhibition of the vascular endothelial growth factor (VEGF) pathway via VEGFR-tyrosine kinase inhibitors (VEGF TKI) or the anti-VEGF antibody bevacizumab, mTOR pathway inhibition, and immune checkpoint inhibitors (ICI) [5, 6]. The gene discussed is VEGFA; the disease is renal cell carcinoma.